We are live on ! Find out more
SPRO icon

Spero Therapeutics
SPRO

35 hedge funds and large institutions have $110M invested in Spero Therapeutics in 2018 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 7

20% more capital invested

Capital invested by funds: $91.2M → $110M (+$18.6M)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.38% less ownership

Funds ownership: 53.99% → 53.62% (-0.38%)

5% less funds holding

Funds holding: 37 → 35 (-2)

29% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 7

Holders
35
Holders Change
-2
Holders Change %
-5.41%
% of All Funds
0.8%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
5
Increased
11
Reduced
7
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
JP Morgan Chase
JP Morgan Chase
New York
+$3.09M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$795K
3
BCM
Bridgeway Capital Management
Texas
+$663K
4
State Street
State Street
Massachusetts
+$384K
5
DCM
DAFNA Capital Management
California
+$298K

Top Sellers

1
RCM
RA Capital Management
Massachusetts
-$5.87M
2
ECM
Endurant Capital Management
California
-$365K
3
LCM
Laurion Capital Management
New York
-$170K
4
DIM
DC Investments Management
Virginia
-$118K
5
TCIM
TIAA CREF Investment Management
New York
-$103K
Name Holding Trade Value Shares
Change 		Change in
Stake
AVAI
1
Atlas Venture Associates IX
Massachusetts
$19.6M – – –
AI
2
Alphabet Inc
California
$15.9M – – –
BI
3
BVF Inc
California
$14.9M +$240K +19,773 +2%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$11.4M – – –
RCM
5
RA Capital Management
Massachusetts
$10.6M -$5.87M -484,000 -39%
RSCM
6
Rock Springs Capital Management
Maryland
$7.48M – – –
VMI
7
VHCP Management II
New York
$6.92M – – –
AG
8
Artal Group
Luxembourg
$4.99M – – –
AIC
9
AWM Investment Company
New York
$4.99M – – –
JP Morgan Chase
10
JP Morgan Chase
New York
$3.65M +$3.09M +255,052 +19,604%
BlackRock
11
BlackRock
New York
$3.6M +$139K +11,427 +5%
Vanguard Group
12
Vanguard Group
Pennsylvania
$1.58M +$795K +65,550 +144%
Northern Trust
13
Northern Trust
Illinois
$945K +$15K +1,234 +2%
BCM
14
Bridgeway Capital Management
Texas
$779K +$663K +54,700 New
State Street
15
State Street
Massachusetts
$451K +$384K +31,673 New
DCM
16
DAFNA Capital Management
California
$421K +$298K +24,544 +491%
California Public Employees Retirement System
17
California Public Employees Retirement System
California
$356K – – –
Geode Capital Management
18
Geode Capital Management
Massachusetts
$290K +$247K +20,396 New
Bank of New York Mellon
19
Bank of New York Mellon
New York
$202K +$172K +14,199 New
Millennium Management
20
Millennium Management
New York
$163K +$138K +11,415 New
Morgan Stanley
21
Morgan Stanley
New York
$157K +$5.79K +477 +5%
California State Teachers Retirement System (CalSTRS)
22
California State Teachers Retirement System (CalSTRS)
California
$136K – – –
Deutsche Bank
23
Deutsche Bank
Germany
$110K -$66.3K -5,466 -41%
AIG
24
American International Group
New York
$55K -$2.5K -206 -5%
SO
25
STRS Ohio
Ohio
$24K – – –
1
2

SPRO Hedge Fund Activity: Q1 2018 in Review

35 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q1 2018, worth a combined $110M — up 20% from $91.2M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of SPRO and 5 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 11 added.

The largest buyer was JP Morgan Chase, adding an estimated $3.09M. The largest seller was RA Capital Management, cutting an estimated $5.87M.

  • 35 institutional investors held Spero Therapeutics (SPRO) as of Q1 2018, down from 37 in Q4 2017.
  • Funds reported $110M of Spero Therapeutics stock for Q1 2018, up 20% quarter-over-quarter.
  • 5 funds opened new Spero Therapeutics positions in Q1 2018 and 7 closed out, a net change of -2 holders.
  • The largest Spero Therapeutics buyer in Q1 2018 was JP Morgan Chase, an estimated $3.09M added.
  • The largest Spero Therapeutics seller in Q1 2018 was RA Capital Management, an estimated $5.87M sold.

Based on aggregated 13F filings for Q1 2018.